Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
暂无分享,去创建一个
Z. Qureshi | P. Lefebvre | R. Jacobs | Xiaoxiao Lu | M. Lafeuille | L. Morrison | F. Kinkead | B. Emond | Linda H Wu | Wasiulla Khan
[1] G. Follows,et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. , 2022, Journal of Clinical Oncology.
[2] A. Deal,et al. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia , 2022, Leukemia & lymphoma.
[3] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[4] Shaun P. Forbes,et al. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. , 2021, Clinical lymphoma, myeloma & leukemia.
[5] M. Davids,et al. Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma , 2021, Blood.
[6] M. Hallek,et al. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.
[7] A. LaCasce,et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. , 2021, The Lancet. Oncology.
[8] J. Pagel,et al. Current and future treatment strategies in chronic lymphocytic leukemia , 2021, Journal of Hematology & Oncology.
[9] Anqi Zhu,et al. Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia , 2021, Journal of the advanced practitioner in oncology.
[10] A. Mato,et al. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia , 2020, Current medical research and opinion.
[11] A. Wiestner,et al. Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. , 2020, The New England journal of medicine.
[12] Á. Illés,et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Byrd,et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.
[14] C. Gillespie,et al. Medication adherence, health care utilization, and spending among privately-insured adults with chronic conditions in the United States, 2010-2016. , 2020, The American journal of medicine.
[15] K. Wada,et al. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States , 2019, Cancer medicine.
[16] J. Mielgo-Ayuso,et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study , 2019, BMC Family Practice.
[17] T. Shanafelt,et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. , 2019, The New England journal of medicine.
[18] Naveen Garg,et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. , 2019, The New England journal of medicine.
[19] Scott E. Smith,et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL , 2018, The New England journal of medicine.
[20] M. Hallek,et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma , 2018, Leukemia.
[21] T. Kipps,et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 , 2018, Haematologica.
[22] E. Hagström,et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence , 2018, Current medical research and opinion.
[23] Fernando Fernandez-Llimos,et al. Economic impact of medication non-adherence by disease groups: a systematic review , 2018, BMJ Open.
[24] E. Jaul,et al. Age-Related Diseases and Clinical and Public Health Implications for the 85 Years Old and Over Population , 2017, Front. Public Health.
[25] J. Byrd,et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. , 2017, Blood.
[26] Jeffrey A Jones,et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. , 2016, The Lancet. Oncology.
[27] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[28] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[29] M. McGuire,et al. Adherence and health care costs , 2014, Risk Management and Healthcare Policy.
[30] Joseph Hanlon,et al. Clinical consequences of polypharmacy in elderly , 2014, Expert opinion on drug safety.
[31] Brian W. Ward,et al. Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010 , 2013, Preventing chronic disease.
[32] P. Sorice,et al. Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice , 2013, PloS one.
[33] D. Sobieraj,et al. Dosing Frequency and Medication Adherence in Chronic Disease , 2012, Journal of managed care pharmacy : JMCP.
[34] Bradley C Martin,et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data , 2009, Current medical research and opinion.
[35] Marsha A Raebel,et al. Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.
[36] J. Reginster,et al. Adherence, patient preference and dosing frequency: understanding the relationship. , 2006, Bone.
[37] M. Robin DiMatteo,et al. Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis , 2002, Medical care.
[38] R. Greil,et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.